Our knowledge on the expression, regulation and roles of the different phosphoinositide 3-kinases (PI3Ks) in platelet signaling and functions has greatly expanded these last twenty years. Much progress has been made in understanding the roles and regulations of class I PI3Ks which produce the lipid second messenger phosphatidylinositol 3,4,5 trisphosphate (PtdIns(3,4,5)P3). Selective pharmacological inhibitors and genetic approaches have allowed researchers to generate an impressive amount of data on the role of class I PI3Kα, β, δ and γ in platelet activation and in thrombosis. Furthermore, platelets do also express two class II PI3Ks (PI3KC2α and PI3KC2β), thought to generate PtdIns(3,4)P2 and PtdIns3P, and the sole class III PI3K (Vps34), known to synthesize PtdIns3P. Recent studies have started to reveal the importance of PI3KC2α and Vps34 in megakaryocytes and platelets, opening new perspective in our comprehension of platelet biology and thrombosis. In this review, we will summarize previous and recent advances on platelet PI3Ks isoforms. The implication of these kinases and their lipid products in fundamental platelet biological processes and thrombosis will be discussed. Finally, the relevance of developing potential antithrombotic strategies by targeting PI3Ks will be examined.
Phosphoinositide 3-kinases in platelets, thrombosis and therapeutics
- Views Icon Views
- Share Icon Share
Agnès Ribes, Antoine Oprescu, Julien Viaud, Karim Hnia, Gaëtan Chicanne, Jean-Marie Xuereb, Sonia Severin, Marie-Pierre Gratacap, Bernard Payrastre; Phosphoinositide 3-kinases in platelets, thrombosis and therapeutics. Biochem J 27 November 2020; 477 (22): 4327–4342. doi: https://doi.org/10.1042/BCJ20190402
Download citation file: